StageZero Life Sciences Ltd. (SZLSF) Stock Price & Analysis
StageZero Life Sciences Ltd. (SZLSF) — price $0.001 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
StageZero Life Sciences Ltd. · SZLSF
StageZero Life Sciences Ltd. focuses on early disease detection and personalized health management through molecular diagnostic testing. Their key product, Aristotle, is a multi-cancer screening test utilizing their proprietary Sentinel Principle platform.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.001 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0005 – $0.0117 | |
| Shares traded on the day | 300 |
Price & events
Other perspectives
Council score for StageZero Life Sciences (SZLSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 1, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 1, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is StageZero Life Sciences (SZLSF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. StageZero Life Sciences Ltd. (SZLSF) is the company analyzed here. It employs 40 people and is led by James R. Howard-Tripp. In Q3 FY2024 it reported revenue of $499,663 and net income of -$399,277.
What do the latest results show for StageZero Life Sciences (SZLSF)?
Short answer · as of
The most recent reported quarter, Q3 FY2024, carried revenue of $499,663.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2024 | $499,663 | -$399,277 | -$0.0033 (diluted) |
| Q2 FY2024 | $390,083 | -$649,460 | -$0.01 (diluted) |
| Q1 FY2024 | $519,589 | -$384,623 | -$0.0031 (diluted) |
What are the financial strengths and risks for StageZero Life Sciences (SZLSF)?
Short answer · as of
The distress and quality screens read Piotroski F 2. Trailing ratios: ROE 481.5% · current ratio 0.04.
What should you watch next at StageZero Life Sciences (SZLSF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $4.32M · EPS -0.17 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q3 FY2024) was filed Sep 30, 2024 — 17 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $4.32M
- EPS estimate
- $-0.17
Measured against a quoted price of $0.001 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SZLSF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SZLSF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: SZLSF Stock
These answers are editorial: 1 of these 1 answer is drawn from the SZLSF research dossier (written Mar 15, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What does StageZero Life Sciences Ltd. do?
StageZero Life Sciences Ltd. is a vertically integrated healthcare company that develops and commercializes molecular diagnostic tests for the early detection of diseases, with a primary focus on cancer. Their main product is the Aristotle multi-cancer panel test, which screens for multiple cancers from a single blood sample using their proprietary Sentinel Principle platform.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 7 from Financial Modeling Prep (FMP) and 8 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com